Opioid antagonists and alcohol consumption;Antagonistas opioides y consumo de alcohol

Revista de Neurologia

Volumn 45, Issue 3, 2007, Pages 155-162

  Barrios De Tomasi, E ^a   Juárez González, Jorge ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Addiction; Alcohol; Alcoholism; Beta endorphins; Opioid antagonists; Opioid system

Indexed keywords

DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; OPIATE ANTAGONIST; OPIATE RECEPTOR;

ALCOHOL CONSUMPTION; ALCOHOLISM; BINDING AFFINITY; DRUG MECHANISM; HUMAN; MODULATION; PROTEIN SECRETION; REVIEW;

EID: 37349014132     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4503.2005624     Document Type: Review

References (97)

1. Seevers MH. Psychopharmacological elements of drug dependence. JAMA 1968; 206: 1263-6.
2. Schuckit MA. Alcoholism: acute treatment. In Schuckit MA, ed. Drug and alcohol abuse: a clinical guide to diagnosis and treatment. New York: Kluwer Academic/Plenum Publishers; 2000. p. 98-118.
3. Hoenicka J, Ampuero I, Ramos-Atance JA. Aspectos genéticos del alcoholismo. Trastornos Adictivos 2003; 5: 213-22.
4. Bierut LJ, Dinwiddie SH, Begleiter H, Crowe RR, Hesselbrock V, Nurnberger JI Jr. Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: a report from the Collaborative Study on the Genetics of Alcoholism. Arch Gen Psychiatry 1998; 55: 982-8.
5. Merikangas KR, Dierker L, Fenton B. Familial factors and substance abuse: implications for prevention. NIDA Res Monogr 1998; 177: 12-41.
6. Wiberg GS, Samson J, Maxwell WB, Coldwell BB, Trenholm HI. Further studies on the acute toxicity of ethanol in young and old rats: relative importance of pulmonary excretion and total body water. Toxicol Appl Pharmacol 1971; 20: 22-9.
7. Juárez J. Neurobiología de las adicciones. In Velázquez M, ed. Temas selectos de neurociencias III. México: Universidad Autónoma Metropolitana; 2004. p. 225-37.
8. Strother WN, Chernet EJ, Lumeng L, Li TK, McBride WJ. Regional central nervous system densities of delta-opioid receptors in alcohol-preferring P, alcohol-nonpreferring NP and unselected Wistar rats. Alcohol 2001; 25: 31-8.
9. Gianoulakis C. Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. Rev Psychol Neurosci 2001; 26: 304-18.
10. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving traits. Proc Natl Acad Sci U S A 1988; 85: 5274-8.
11. Yim HJ, Gonzales RA. Ethanol-induced increase in dopamine extracellular concentration in rat nucleus accumbens are accounted for increased release and not uptake inhibition. Alcohol 2000; 22: 107-15.
12. Budygin EA, Phillips PE, Wightman RM, Jones SR. Terminal effects of ethanol on dopamine dynamics in rat nucleus accumbens an in vitro voltametric study. Synapse 2001; 42: 77-9.
13. Genazzani AR, Nappi G, Facchinetti F, Mazella GL, Parrini D, Sinforiani E, et al. Central deficiency of beta-endorphin in alcohol addicts. J Clin Endocrinol Metab 1982; 55: 583-6.
14. Zalewska-Kaszubska J, Czarnecka E. Deficit in beta-endorphin peptide and tendency to alcohol abuse Peptides 2005; 26: 701-5
15. Grisel JE, Mogil JS, Grahame NJ, Rubinstein M, Belknap JK, Crabbe JC, et al. Ethanol oral self-administration is increased in mutant mice with decreased beta-endorphin expression. Brain Res 1999; 835: 62-7.
16. Burov IV, Treskov VG, Iukhananov RI, Kovalenko AK. Beta-endorphin and endogenous alcohol level of the blood in alcoholic patients. Biull Eksp Biol Med 1984; 98: 578-9.
17. Gianoulakis C. Characterization of the effects of acute ethanol administration on the release of beta-endorphin peptides by the rat hypothalamus. Eur J Pharmacol 1990; 180: 21-9.
18. Gianoulakis C, Krishnan B, Thavundayil J. Enhanced sensitivity of pituitary β-endorphine to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry 1996; 53: 250-7.
19. Zalewska-Kaszubska J, Gorska D, Dyr W, Czarnecka E. Effect of acute administration of ethanol on beta-endorphin plasma level in ethanol preferring and non-preferring rats chronically treated with naltrexone. Pharmacol Biochem Behav 2006; 85: 155-9
20. Kiefer F, Horntrich M, Jahn H, Wiedemann K. Is withdrawal-induced anxiety in alcoholism based on β-endorphine deficiency? Psychopharmacology 2002; 162: 433-7.
21. Eckersell CB, Popper P, Micevych PE. Estrogen-induced alteration of mu-opioid receptor immunoreactivity in the medial preoptic nucleus and medial amygdala. J Neurosci 1998; 18: 3967-76.
22. Micevych PE, Eckersell CB, Brecha N, Holland KL. Estrogen modulation of opioid and cholecystokinin systems in the limbic-hypothalamic circuit. Brain Res Bull 1997; 44: 335-43.
23. Micevych PE, Rissman EF, Gustafsson JA, Sinchak K Estrogen receptor-alpha is required for estrogen-induced mu-opioid receptor internalization. J Neurosci Res 2003; 71: 802-10.
24. Sinchak K, Micevych P. Visualizing activation of opioid circuits by internalization of G protein-coupled receptors. Mol Neurobiol 2003; 27: 197-222.
25. Messiha FS. Steroidal actions and voluntary drinking of ethanol by male and female rats. Prog Biochem Pharmacol 1981; 18: 205-15.
26. Juárez J, Barrios de Tomasi E., rgen M. Effects of estradiol treatment on voluntary and forced alcohol consumption in male rats. Pharmacol Biochem Behav 2002; 71: 259-68.
27. Juárez J, Vázquez-Cortés C, Barrios de Tomasi E. Different stages in the temporal course of estrogen treatment produce opposite effects on voluntary alcohol consumption in male rats. Alcohol 2005; 36: 55-61.
28. Gardell LR, Hubbell CHL, Reid LD. Naltrexone persistently reduces rats' intake of a palatable alcoholic beverage. Alcohol Clin Exp Res 1996; 20: 584-8.
29. Reid LD, Gardell LR, Chattopadhyay S, Hubbell CL. Periodic naltrexone and propensity to take alcoholic beverage. Alcohol Clin Exp Res 1996; 20: 1329-34.
30. Gianoulakis, C. Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. J Psychiatry Neurosci 2001; 26: 304-18.
31. Oswald LW, Wand GS. Opioids and alcoholism. Physiol Behav 2004; 81: 339-58.
32. Cowen MS, Lawrence AJ. The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psych 1999; 23: 1171-212.
33. Coonfield DL, Hill KG, Kaczmarek HJ, Ferraro FM III, Kiefer SW. Low doses of naltrexone reduce palatability and consumption of ethanol in outbred rats. Alcohol 2002; 26: 43-7.
34. Froehlich JC, Li TK. Opioid involvement in alcohol drinking. Ann N Y Acad Sci 1994; 739: 156-67.
35. O'Malley SS. Opioid antagonist in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. Alcohol Alcohol 1996; 1: 77-81.
36. Holter SM, Spanagel R. Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats. Psychopharmacology 1999; 145: 360-69.
37. Tomkins DM, Sellers EM. Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence. CMAJ 2001; 164: 817-21.
38. Guardia SJ. Tratamiento farmacológico de la dependencia de alcohol. Coloquios en drogodependencia. Barcelona; 2001.
39. Al Quatari M, Bouchenafa O, Littleton J. Mechanisms of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 1998; 22: 810-4.
40. Littleton J, Zieglgänsberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 2003; 12 (Suppl 1): S3-11.
41. Boothby LA, Doering PL. Acamprosate for the treatment of alcohol dependence. Clin Ther 2005; 27: 695-714.
42. Moncrieff J, Drummond DC. New drug treatments for alcohol problems: a critical appraisal. Addiction 1997; 92: 939-47.
43. Martijena ID, Bustos SG, Bertotto ME, Molina VA. Antidepressants attenuate both the enhanced ethanol intake and ethanol-induced anxiolytic effects in diazepam withdrawn rats. Eur Neuropsychopharmacol 2005; 15: 119-30.
44. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152: 391-7.
45. Gardell LR, Whalen CA, Chattophadyay S, Cavallaro CA, Hubbell CL, Reid LC. Combination of naltrexone and fluoxetine on rats propensity to take alcoholic beverage. Alcohol Clin Exp Res 1997; 21: 1435-9.
46. Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 1990; 47: 490-8.
47. Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Kadlec KE, Sykora K. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 1987; 41: 266-74.
48. Naranjo CA, Sullivan JT, Kadlec KE, Woodley-Remus DV, Kennedy G, Sellers EM. Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clin Pharmacol Ther 1989; 46: 301-9.
49. Pivac N, Muck-Seler D, Mustapic M, Nenadic-Sviglin K, Kozaric-Kovacic D. Platelet serotonin concentration in alcoholic subjects. Life Sci 2004; 76: 521-31.
50. Fu Q, Heathy AC, Bucholz KK, Nelson E, Goldberg J, Lyons MJ, et al. Shared genetic risk of major depression, alcohol dependence, and marijuana dependence: contribution of antisocial personality disorder in men. Arch Gen Psychiatry 2002; 59: 1125-33.
51. Driessen M, Meier S, Hill A, Wetterling T, Lange W, Junghanns K. The course of anxiety, depression and drinking behaviors after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol Alcohol 2001; 36: 249-55.
52. Rezvani AH, Overstreet DH, Mason GA, Janowsky DS, Hamedi M, Clark E, et al. Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine and a thyrotropin-release hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats. Alcohol Alcohol 2000; 35: 76-83.
53. Hasnat A, Haider S, Perveen T, Kidwai IM, Haleem DJ. Decrease of ethanol intake following repeated injection of serotonin-1A agonist in rats: relationship with receptor responsiveness. J Coll Physicians Surg Pak 2003; 13: 305-8.
54. McKenzie-Quirk SD, Miczek KA. 5-HT1A agonists: alcohol drinking in rats and squirrel monkeys. Psychopharmacology 2003; 167: 145-52.
55. Myers RD, Lankford MF: Suppression of alcohol preference in high alcohol drinking rats. Efficacy of amperozide versus naltrexone. Neuropsychopharmacology 1996; 14: 139-49.
56. Lankford MF, Myers RD. Opiate and 5-HT2A receptors in alcohol drinking: preference in HAD rats is inhibited by combination treatment with naltrexone and amperozide. Alcohol 1996; 13: 53-7.
57. Hadal KA, Schauben JL, Salamone FR. Naloxone. Ann Emerg Med 1983; 12: 438-45.
58. Ngai SH, Berkowitz BA, Yang JC, Hempstead J, Spector S. Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology 1976; 44: 398-401.
59. Sinclair JD. Drugs to decrease alcohol drinking. Ann Med 1990; 22: 357-62.
60. Sinden JD, Marfaing-Jallat P, Magnen J. The effect of naloxone on intragastric ethanol self-administration. Pharmacol Biochem Behav 1983; 19: 1045-8.
61. Davidson D, Amit Z. Effects of naloxone on limited-access ethanol drinking in rats. Alcohol Clin Exp Res 1996; 20: 664-9
62. Hyytia P, Ingman K, Soini SL, Laitinen JT, Korpi ER. Effects of continuous opioid receptor blockade on alcohol intake and up-regulation of opioid receptor subtype signalling in a genetic model of high alcohol drinking. Naunyn-Schmiedberg's Arch Pharmacol 1999; 360: 391-401.
63. González JP, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35: 192-213.
64. Parkes H, Sinclair JD. Reduction of alcohol drinking and upregulation of opioid receptors by oral naltrexone in AA rats. Alcohol 2000; 21: 215-21.
65. Davidson D, Amit Z. Effect of ethanol drinking and naltrexone on subsequent drinking in rats. Alcohol 1997; 14: 581-4.
66. Méndez M, Cruz C. Mecanismos cerebrales de reforzamiento del alcohol. II. Bases neuroquímicas: papel del sistema opioide. Salud Mental 1999; 22: 52-9.
67. Volpicelli JR, Clay KL, Watson NT, O'Brien CP. Naltrexone in the treatment of alcoholism: predicting response to naltrexone. J Clin Psychiatry 1995; 56: 39-44.
68. Stromberg MF, Volpicelli JR, O'Brien CP. Effects of naltrexone administered repeatedly across 30 and 60 days on ethanol consumption using a limited access procedure in the rat. Alcohol Clin Exp Res 1998; 22: 2186-91.
69. Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, et al. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol 2006; 26: 610-25.
70. Weiss F, Porrino L. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci 2002; 22: 3332-7.
71. Weiss F, Lorang MT, Bloom FE, Koob GF. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J Pharmacol Exp Ther 1993; 267: 250-8.
72. Philpot RM, Kirstein CL. The effects of repeated alcohol exposure on the neurochemistry of the periadolescent nucleus accumbens septi. Neuroreport 1998; 9: 1359-63.
73. Lee YK, Park SW, Kim YK, Kim DJ, Jeong J, Myrick H, et al. Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. Alcohol Alcohol 2005; 40: 297-301.
74. Williams KL, Woods JH. Oral ethanol-reinforced responding in rhesus monkeys: effects of opioid antagonists selective for the μ, κ or δ-receptor. Alcohol Clin Exp Res 1998; 22: 1634-9.
75. Phillips TJ, Wenger CD, Dorow JD. Naltrexone effects on ethanol drinking acquisition and on established ethanol consumption in C57BL/6J mice. Alcohol Clin Exp Res 1997; 21: 691-702.
76. Hill KG, Kiefer W. Naltrexone treatment increases the aversiveness of alcohol for outbred rats. Alcohol Clin Exp Res 1997; 21: 637-42.
77. Juárez J, Gutiérrez-Larios I, Valdez-Aguilar R. Naltrexone therapy in alcoholic patients: a comparison between continuous and intermittent treatment [en preparación].
78. Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 2001; 36: 2-10.
79. Bienkowski P, Kostowski W, Koros E. Ethanol-reinforced behavior in the rat: effects of naltrexone. Eur J Pharmacol 1999; 374: 321-7.
80. Juárez J, Barrios de Tomasi E. Alcohol consumption is enhanced alter naltrexone treatment. Alcoholism Clin Exp 2007; 31: 260-4.
81. Cowen MS, Rezvani AH, Jarrott B, Lawrence AJ. Ethanol consumption by fawn-hooded (FH) rats following abstinence: effect of ntx and changes in mu-opioid receptor density. Alcohol Clin Exp Res 1999; 23: 1008-14.
82. Boyle AEL, Stewart RB, Macenski MJ, Spiga R, Johnson BA, Meisch RA. Effects of acute and chronic doses of naltrexone on ethanol self-administration in rhesus monkeys. Alcohol Clin Exp Res 1998; 22: 359-66.
83. Kornet M, Goosen C, Van Ree JM. Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys. Psychopharmacology 1991; 104: 367-76.
84. Goodwin FL, Campisi M, Babinska I, Amit Z. Effects of naltrexone on the intake of ethanol and flavored solutions in rats. Alcohol 2001; 25: 9-19.
85. Rasmussen, DD, Bryant, CA, Boldt, BM, Colasurdo, EA, Levin, N, Wilkinson CW. Acute alcohol effects on opiomelanocortinergic regulation. Alcohol Clin Exp Res 1998; 22: 789-801.
86. Dixon R, Howes J, Gentile, J. Nalmefene: intravenous safety and kinetics of a new opioid antagonist. Clin Pharmacol Ther 1986; 39: 49-53.
87. Gal TJ, Difazio CA, Cosmo A, Dixon R. Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther 1986; 40: 537-42.
88. Michel ME, Bolger G, Weissman BA. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 1985; 7: 175-7.
89. Drobes DJ, Anton RF, Thomas SE, Voronin K. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology 2003; 28: 755-64.
90. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999; 56: 719-24.
91. Drobes DJ, Anton RF, Thomas SE, Voronin K. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 2004; 28: 1362-70.
92. June HL, Grey C, Warren-Reese C, Durr LF, Ricks-Cord A, Johnson A, et al. The opioid antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res 1998; 22: 2174-85.
93. Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D, et al. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol 1987; 27: 233-9.
94. Stromberg MF, Casale M, Volpicelli JR, O'Brien CP. A comparison of the effects of the opioid antagonists naltrexone, naltrindole and β-funal-trexamine on ethanol consumption in the rat. Alcohol 1998; 15: 281-9.
95. Ciccocioppo R, Martin-Fardon R, Weiss F. Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacology 2002; 27: 391-9.
96. Mitchell JM, Liang MT, Fields HLA. Single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats. Psychopharmacology (Berl) 2005; 182: 384-92.
97. Kim SG, Stromberg M, Kim MJ, Volpicelli JR, Park JM. The effect of antagonists selective for μ - and ?-opioid receptor subtypes on alcohol consumption in C57BL/6 mice. Alcohol 2000; 22: 85-90.